injective

On November 3, 2026, a significant development emerged from the regulatory filings of the Canary Staked INJ ETF.
Canary filed Form 8-A with the SEC, registering the ETF shares under Section 12(b) of the Securities Exchange Act of 1934.
And here is the most important part:
NASDAQ HAS APPROVED THE APPLICATION TO LIST THE CANARY STAKED INJ ETF!
Expected ticker: INJC
This is no longer just an ETF rumor. It is a real regulatory milestone in Injective’s journey toward entering the traditional U.S. financial markets.
1. NASDAQ’S LISTING APPROVAL – WHY IS THIS SUCH AN IMPORTANT MILESTONE?
The Injective community has been waiting for an INJ ETF for a long time.
We have witnessed:
The initial ETF filing.Multiple S-1/A amendments.Canary continuing to refine the fund’s structure.The regulatory process gradually moving forward.
And now, Form 8-A confirms that Nasdaq has approved the application to list the ETF shares.
This is a significant step forward.
Nasdaq’s approval indicates that the ETF has cleared an important milestone in the process of preparing its shares for exchange trading.
INJ is moving closer to the gateway of traditional financial markets.
2. CANARY STAKED INJ ETF – MORE THAN JUST A PRICE-TRACKING ETF
One distinctive feature of the Canary Staked INJ ETF is its proposed structure, which directly holds INJ and participates in staking.
According to the prospectus:
🔹 The ETF aims to provide exposure to the price of INJ.
🔹 The fund may stake a large portion of its INJ holdings.
🔹 Investors could gain exposure to INJ through traditional brokerage accounts.
🔹 The creation of new ETF shares could generate actual demand for INJ when fresh capital enters the fund.
This is what makes the ETF particularly interesting from an Injective tokenomics perspective.
If the fund attracts net inflows, demand for INJ could increase.
And if the INJ acquired by the fund is subsequently staked, a portion of the circulating supply could become locked in staking.
However, the actual impact will depend on the ETF’s capital flows after launch.
3. WHAT COULD THIS CHANGE FOR INJ?
In my view, the biggest impact of an ETF is not just its short-term price reaction.
If the INJ ETF officially launches and attracts capital, Injective could benefit from:
🔹 Access to capital from traditional investors.
🔹 Greater visibility in the U.S. financial markets.
🔹 Potential demand for INJ through ETF share creation.
🔹 Increased attention from institutional investors.
🔹 A new catalyst for the RWA narrative and bringing traditional finance on-chain.
In particular, for a project focused on real-world asset tokenization and on-chain financial applications, an ETF could expand its potential investor base.
But we also need to remain realistic:
An ETF does not automatically make INJ’s price rise. Actual capital flows will be the key factor.
4. BTCVN4’S PERSPECTIVE
Honestly, this is one of the milestones the INJ community has been waiting for over a long period.
I believe an ETF could become an important long-term catalyst for Injective.
However, I will not make an investment decision based solely on Nasdaq’s listing approval.
I will be watching:
The official ETF trading date.Fund inflows during the first few days.The actual amount of INJ held by the fund.INJ’s price reaction and the broader crypto market.
If the ETF launches and attracts sustainable capital inflows, that could be the factor that significantly changes INJ’s supply-demand dynamics.
CONCLUSION
NASDAQ HAS APPROVED THE LISTING OF THE CANARY STAKED INJ ETF – A SIGNIFICANT STEP FORWARD IN INJ’S ETF JOURNEY!
The November 3, 2026, Form 8-A filing marks an important development.
From an initial ETF filing, through multiple amendments, to Nasdaq’s approval of the listing application.
Injective is moving closer to gaining access to the traditional U.S. financial markets.
I will continue monitoring updates from the SEC, Canary Capital, and Nasdaq.
The INJ ETF may be approaching its trading debut. But the most important factor will still be actual capital flows after the ETF launches.
What do you think about this milestone? Could the ETF become a catalyst for a new growth cycle for Injective?
$INJ #injective #BTCVN4 #crypto #RWA #BinanceSquare
— BTCVN4

The way traditional investors access cryptocurrencies is gradually evolving and @Injective could soon become part of it too.
Canary Capital's Staked INJ ETF (INJC) is designed to give investors exposure to $INJ through a traditional brokerage account without requiring them to purchase the cryptocurrency directly, manage private keys or operate their own crypto wallets.
The important part of 𝗜𝗡𝗝𝗖 is that it also introduces a staking component, allowing the fund to participate in 𝗜𝗻𝗷𝗲𝗰𝘁𝗶𝘃𝗲'𝘀 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝘀𝘁𝗮𝗸𝗲 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 and earn additional INJ through staking rewards.
> How exactly does this ETF work? > How are its assets managed? > How do staking rewards contribute to its value. > What should investors understand before considering it?
Let's break it down
➥ 𝗛𝗼𝗹𝗱𝗶𝗻𝗴 𝗜𝗡𝗝 𝘃𝘀 𝗢𝘄𝗻𝗶𝗻𝗴 𝗜𝗡𝗝𝗖 𝗦𝗵𝗮𝗿𝗲𝘀
Before understanding how the ETF operates, it's important to know the difference between directly holding $INJ and purchasing shares in INJC.
When you buy 𝗜𝗡𝗝 directly, you own the cryptocurrency itself.
You can transfer it between wallets, stake it, use it within the Injective ecosystem or hold it as an investment.
However, when you purchase 𝗜𝗡𝗝𝗖 shares, you become a shareholder in a fund that holds the underlying $INJ .
You don't personally own or control the individual tokens held by the fund.
Instead, your shares represent a proportional beneficial interest in the trust's assets.
Their value is linked to the fund's underlying holdings, after accounting for expenses and liabilities the fund has.
➥ 𝗛𝗼𝘄 𝗗𝗼𝗲𝘀 𝗦𝘁𝗮𝗸𝗶𝗻𝗴 𝗪𝗼𝗿𝗸 𝗜𝗻𝘀𝗶𝗱𝗲 𝗜𝗡𝗝𝗖?
Staking is one of the most important feature of this product. According to the prospectus, 𝗖𝗮𝗻𝗮𝗿𝘆 anticipates staking at least 𝟵𝟬% of the fund's INJ holdings under normal circumstances.
Some INJ may remain unstaked to support expected redemptions, cover fund expenses or protect the fund's assets.
𝗕𝘂𝘁 𝗵𝗼𝘄 𝗱𝗼𝗲𝘀 𝘁𝗵𝗲 𝗮𝗰𝘁𝘂𝗮𝗹 𝘀𝘁𝗮𝗸𝗶𝗻𝗴 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝘄𝗼𝗿𝗸?
The process involves some key participants:
> 𝗖𝗮𝗻𝗮𝗿𝘆 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 is responsible for administering the staking programme and selecting the staking providers.
> Selected providers delegate the tokens to verified Injective validators
> 𝗕𝗶𝘁𝗚𝗼 maintains custody of the fund's $INJ and controls the associated private keys.
One important detail is that the fund will not operate its own validator nodes.
𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘁𝗼 𝘁𝗵𝗲 𝘀𝘁𝗮𝗸𝗶𝗻𝗴 𝗿𝗲𝘄𝗮𝗿𝗱𝘀?
The fund receives a portion of the rewards generated through staking.
After applicable staking fees, the remaining rewards contribute to the fund's assets and daily Net Asset Value.
These rewards are generally restaked to help the fund accumulate additional INJ over time.
This means shareholders benefit from staking through the value of their ETF shares rather than receiving direct staking payouts.
➥ 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱 𝗜𝗡𝗝𝗖'𝘀 𝗡𝗲𝘁 𝗔𝘀𝘀𝗲𝘁 𝗩𝗮𝗹𝘂𝗲 (𝗡𝗔𝗩)
𝗜𝗡𝗝𝗖 uses Net Asset Value (NAV) to measure the underlying value of each share.
This value reflects the fund's $INJ holdings, the staking rewards it accumulates and the expenses and liabilities it has.
It's calculated once each trading day using a 60-minute average of $INJ prices across major trading platforms based on 𝗖𝗼𝗶𝗻𝗱𝗲𝘀𝗸 𝗜𝗻𝗷𝗲𝗰𝘁𝗶𝘃𝗲 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸 which uses 𝟰 𝗣𝗠 𝗘𝗧 as its daily reference time.
Since INJ trades 24/7, weekend price movements won't be reflected in a new NAV until the next exchange trading day.
➥ 𝗧𝗵𝗲 𝟮𝟭-𝗗𝗮𝘆 𝗨𝗻𝗯𝗼𝗻𝗱𝗶𝗻𝗴 𝗣𝗲𝗿𝗶𝗼𝗱 𝗮𝗻𝗱 𝗜𝗡𝗝𝗖'𝘀 𝗟𝗶𝗾𝘂𝗶𝗱𝗶𝘁𝘆 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁
Staking provides the opportunity to earn additional INJ but it also introduces a liquidity challenge.
On Injective, when delegated INJ is unstaked, it enters a 21-day unbonding period.
During this period:
> The tokens remain locked. > They cannot be transferred. > They do not earn staking rewards.
This creates an important consideration for an ETF that needs to process redemption requests.
Authorized Participants can submit redemption orders on any business day when the exchange is open.
𝗖𝗮𝗻𝗮𝗿𝘆 also plans to keep some $INJ unstaked as a liquidity reserve, allowing the fund to handle redemption requests without waiting for the full unbonding period.
The fund's prospectus also states that redemptions will generally be settled on the second business day after an order is placed.
➥ 𝗛𝗼𝘄 𝗗𝗼𝗲𝘀 𝗜𝗡𝗝𝗖 𝗠𝗮𝗻𝗮𝗴𝗲 𝘁𝗵𝗲 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗕𝗲𝘁𝘄𝗲𝗲𝗻 𝗠𝗮𝗿𝗸𝗲𝘁 𝗣𝗿𝗶𝗰𝗲 𝗮𝗻𝗱 𝗡𝗔𝗩?
An ETF's market price doesn't always match its underlying NAV.
INJC shares may trade above or below their NAV depending on market demand, liquidity and other market conditions.
𝗙𝗼𝗿 𝗲𝘅𝗮𝗺𝗽𝗹𝗲:
> If INJC shares trade above NAV, they are trading at a premium. > If they trade below NAV, they are trading at a discount.
To manage these differences, the fund uses a 𝗰𝗿𝗲𝗮𝘁𝗶𝗼𝗻 and 𝗿𝗲𝗱𝗲𝗺𝗽𝘁𝗶𝗼𝗻 mechanism involving Authorized Participants (APs).
𝗪𝗵𝗼 𝗮𝗿𝗲 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘇𝗲𝗱 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀?
These are eligible financial institutions typically 𝗯𝗿𝗼𝗸𝗲𝗿-𝗱𝗲𝗮𝗹𝗲𝗿𝘀 or other qualified financial firms authorized to create and redeem large blocks of ETF shares directly with the fund.
The process works in two directions:
> When shares trade above NAV:
Authorized Participants can create additional shares by providing the required INJ or cash to the fund.
The additional supply can reduce the premium between the market price and NAV.
> When shares trade below NAV:
Authorized Participants can purchase existing shares in the market and redeem them with the fund in exchange for the corresponding INJ or cash.
This can help reduce the discount between the market price and NAV.
> How large are these transactions?
INJC's prospectus specifies that creation and redemption orders are processed in blocks of 𝟭𝟬,𝟬𝟬𝟬 𝘀𝗵𝗮𝗿𝗲𝘀.
Ordinary investors cannot directly create or redeem these shares with the fund.
They purchase and sell individual shares through the exchange or their brokerage accounts.
➥ 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱 𝗜𝗡𝗝𝗖'𝘀 𝗙𝗲𝗲 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲
Investors should understand two key costs associated with the fund:
> Annual Sponsor Fee
The proposed fee is 1.10% per year, accrued daily and paid monthly.
> Staking Fees
The fund expects to pay staking providers 30% of the rewards generated. The remaining 70% contributes to the fund's value.
These costs matter because they reduce the value retained by the fund and can affect its NAV over time.
➥ 𝗙𝗶𝗻𝗮𝗹 𝗧𝗵𝗼𝘂𝗴𝗵𝘁𝘀
Injective continues to move closer to traditional financial markets and INJC could become another important milestone in that journey.
Canary has already signaled that the ETF is coming soon, and its structure offers a new way to access Injective while incorporating staking into the investment.
With its launch approaching, understanding how INJC works has never been more relevant.
#injective #INJ #ETFs #WallStreetNews #crypto